Emergent BioSolutions vs Prestige Consumer Healthcare
EBS and PBH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EBS and PBH compare
Prestige Consumer Healthcare is the larger company, worth 6.8 times as much as Emergent BioSolutions ($2.1B against $310M).
Prestige Consumer Healthcare grew revenue faster over the last twelve months (5.1% versus −17.7% for Emergent BioSolutions).
Prestige Consumer Healthcare keeps more of each dollar of sales as profit, with a net margin of 13.3% compared with −40.2% at Emergent BioSolutions.
Prestige Consumer Healthcare scores higher on the StockData Score (11 against 7 for Emergent BioSolutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EBS | PBH |
|---|---|---|
| Size and price | ||
| Market cap | $310M | $2.1B |
| Share price | $6.04 | $44.17 |
| Change, 1 year | −45.0% | −26.9% |
| Change, 5 years | −84.9% | −24.2% |
| Beta (5Y) | 1.85 | 0.43 |
| Employees | 900 | 890 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.6× |
| P/S | 0.5× (better) | 1.8× |
| P/B | 1.0× (better) | 1.1× |
| EV/EBITDA | – | 12.6× |
| P/FCF | 1.6× (better) | 9.8× |
| FCF yield | 60.8% (better) | 10.2% |
| Fair value | $21.23 | $65.57 |
| Margin of safety | 71.5% (better) | 32.6% |
| Growth | ||
| Revenue growth (TTM) | −17.7% | 5.1% (better) |
| Revenue growth, 5Y average | −14.0% | 2.9% (better) |
| Net income growth (TTM) | −443% | −22.8% (better) |
| EPS growth (TTM) | −486% | −19.6% (better) |
| EPS growth, 5Y average | −30.4% | 3.8% (better) |
| Profitability | ||
| Gross margin | 48.4% | 52.5% (better) |
| Operating margin | −27.7% | 25.0% (better) |
| Net margin | −40.2% | 13.3% (better) |
| FCF margin | 29.0% (better) | 18.4% |
| Return on equity | −58.2% | 8.2% (better) |
| Return on invested capital | −17.3% | 8.1% (better) |
| Financial health | ||
| Debt / equity | 1.62 | 1.07 (better) |
| Net debt / EBITDA | – | 6.20 |
| Interest coverage | −4.0× | – |
| Current ratio | 4.58 (better) | 2.92 |
| Altman Z-score | 0.34 | 1.52 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 8.8% (better) | 2.2% |
| Shareholder yield | 8.8% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 87.1% | 113% |
| Held by insiders | 6.0% | 1.4% |
| Insider net buying, 12 months | −$986K | −$203K (better) |
| Short interest, % of float | 20.9% | 9.1% |
Go deeper
- EBS stock overview
- EBS income statement
- EBS valuation and score
- PBH stock overview
- PBH income statement
- PBH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.